View this email in your browser
You are receiving this email because of your relationship with InveniAI. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
March 17th, 2017 SUBSCRIBE TO EvolverAI BOT

EvolverAI IS AN ARTIFICIAL INTELLIGENCE PLATFORM BY BIOXCEL,
DESIGNED TO OPTIMIZE THERAPEUTIC VALUE OF DRUGS, THERAPEUTIC MODALITIES AND DISEASES

Our partners leverage EvolverAI to augment R&D decisions and increase
probability of success (POS) by performing complex therapeutic area focused queries with with hundreds-to-thousands of proprietary therapeutic area specific probes designed by our drug discovery and translational experts resulting in disease association maps that are further analyzed using proprietary, predictive algorithms to generate new hypotheses
(right drug--right disease--right patient)

Need for Transformative Approaches to Create
Patient Solutions in Rare Diseases
BioXcel EvolverAI Platform as One of the Approaches:
AI Driven Identification of a Drug for Therapeutic Intervention in NF2

Identified BXCL101 which can reverse the pathophysiology of NF2 by inhibiting the proteasome degradation and thereby rescue LATS1/2 and phosphorylation of YAP1; An underlying cause of the disease resulting from mutation of NF2 gene (merlin)

Preclinical and Human POC established for the hypothesis
IND exemption & orphan drug designation granted by the US FDA
This message was sent from marketing@inveniai.com to marketing@inveniai.com
InveniAI, 780 East Main Street, Branford, CT, 06405


Update Profile/Email Address | Forward Email | Report Abuse